Bristol Myers Squibb made several acquisitions to offset pipeline flaws, but its midterm outlook is disappointing. Read why I ...

Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus ...

Bristol-Myers Squibb's Q1 2024 earnings has resulted in a drop in its share price in trading today. Read why BMY might ...

Corcept Therapeutics Incorporated CORT reported first-quarter 2024 earnings of 25 cents per share, which beat the Zacks Consensus Estimate of 21 cents. The company had reported earnings of 14 cents ...

Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably, causing symptoms like fatigue, jaundice, ...

Despite showing effectiveness in late-stage trials, up to 25 per cent of all potential treatments never make it to market, ...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ...

The incremental benefits in median survival have been modest in the past 11 years with the recent approval of Onivyde in the NALIRIFOX regimen demonstrating a 1.9 month survival benefit compared to ...

The upcoming report from Bristol Myers Squibb (BMY) is expected to reveal quarterly loss of $4.51 per share, indicating a decline of 320% compared to the year-ago period. Analysts forecast revenues of ...

In its first quarter 2024 results statement, Bristol Myers Squibb beat expectations on revenues, which increased 5% to $11.9 billion, although it posted a loss per share of $5.89, due to charges from ...